While TLR3/TLR4-TRIF activation drives the progression of drug-induced liver injury, ischemia-reperfusion liver injury, and autoimmune hepatitis, TRIF exhibits a dual role in ALD and MASLD/MASH. Here, TICAM1 is linked to autoimmune hepatitis.